Ingrida Verbiene

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Kheir, Alaa; Johannsdottir, Berglind; Gronn-Weiss, Alexandra; Liu, Lisa L. et al.

Ingår i Acta Oncologica, s. 1355-1364, 2025

• DOI för Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab
• Ladda ner fulltext (pdf) av Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease

Ullén, Anders; Aljabery, Firas; Dahlman, Pär; Falkman, Karin et al.

Ingår i Scandinavian journal of urology, s. 76-82, 2025

• DOI för Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease
• Ladda ner fulltext (pdf) av Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease

Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

Holmsten, Karin; Eknert, Johanna; Ofverholm, Elisabeth; Papantoniou, Dimitrios et al.

Ingår i Clinical Genitourinary Cancer, 2023

• DOI för Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
• Ladda ner fulltext (pdf) av Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial

Dijkstra, E. A.; Zwart, W. H.; Nilsson, P. J.; Putter, H. et al.

Ingår i ESMO Open, 2023

• DOI för The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial

Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma

Liedberg, Fredrik; Kjellstrom, Sofia; Lind, Anna-Karin; Sherif, Amir et al.

Ingår i Scandinavian journal of urology, s. 137-146, 2022

• DOI för Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma
• Ladda ner fulltext (pdf) av Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Kheir, Alaa; Johannsdottir, Berglind; Gronn-Weiss, Alexandra; Liu, Lisa L. et al.

Ingår i Acta Oncologica, s. 1355-1364, 2025

• DOI för Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab
• Ladda ner fulltext (pdf) av Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease

Ullén, Anders; Aljabery, Firas; Dahlman, Pär; Falkman, Karin et al.

Ingår i Scandinavian journal of urology, s. 76-82, 2025

• DOI för Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease
• Ladda ner fulltext (pdf) av Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease

Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

Holmsten, Karin; Eknert, Johanna; Ofverholm, Elisabeth; Papantoniou, Dimitrios et al.

Ingår i Clinical Genitourinary Cancer, 2023

• DOI för Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
• Ladda ner fulltext (pdf) av Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial

Dijkstra, E. A.; Zwart, W. H.; Nilsson, P. J.; Putter, H. et al.

Ingår i ESMO Open, 2023

• DOI för The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial

Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma

Liedberg, Fredrik; Kjellstrom, Sofia; Lind, Anna-Karin; Sherif, Amir et al.

Ingår i Scandinavian journal of urology, s. 137-146, 2022

• DOI för Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma
• Ladda ner fulltext (pdf) av Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma